Open an account

PAVmed

PAVM · NASDAQ

$2.23−$0.02 (−0.89%)TodayMarket closed ·
Prev close $2.25

About PAVM

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. The company is headquartered in New York City, New York and currently employs 41 full-time employees. The company went IPO on 2016-07-27. The firm operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.

Employees
41
Headquarters
New York City, New York
Listed
Jul 27, 2016
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
pavmed.com

PAVM key statistics

Market cap
17.83M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
22.40K
Volume
6.13K
Open price
$2.27
High today
$2.37
Low today
$2.14
52 Week high
$28.44
52 Week low
$2.20

PAVmed (PAVM) at a glance

As of Oct 20, 2026, PAVmed (PAVM) shares are priced at $2.23, giving the company a market cap of 17.83M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.14 and $2.37. The current price is 4.4% above the day's low and 5.9% below its high.

Volume so far is 6.13K shares, below the average of 22.40K shares a day.

Over the past year PAVmed has ranged from $2.20 to $28.44, and now sits 0% of the way up that range.

PAVmed met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.87 per share against an estimate of -$0.4794.

The average analyst price target is $37.23, 1569.5% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $37.23
Low
$16.16
Now
$2.23
High
$59.85

PAVM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 253.1% on average.

  1. Q3 FY24: reported $43.20 per share against an estimate of $60.44
  2. Q4 FY24: reported $8.70 per share against an estimate of -$17.44
  3. Q1 FY25: reported $10.20 per share against an estimate of -$3.98
  4. Q2 FY25: reported -$22.20 per share against an estimate of -$3.98
  5. Q3 FY25: reported -$8.70 per share against an estimate of -$5.20
  6. Q4 FY25: reported -$5.52 per share against an estimate of -$5.51
  7. Q1 FY26: reported -$4.42 per share against an estimate of -$0.714
  8. Q2 FY26: reported -$0.87 per share against an estimate of -$0.4794

PAVM news

  • Press releasePRNewswire

    Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

  • PAVmed Q2 2026 Earnings Call: Complete Transcript

  • Press releasePRNewswire

    PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

  • Press releasePRNewswire

    Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

  • Press releasePRNewswire

    Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

  • Press releasePRNewswire

    Lucid Diagnostics to Participate in Upcoming Investor Conferences

  • Press releasePRNewswire

    PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026

  • Press releasePRNewswire

    Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026

Similar companies

Companies in the same industry as PAVmed

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.